Treatment of postmenopausal osteoporosis

British Medical Journal

Volumn 330, Issue 7496, 2005, Pages 859-860

  Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ESTROGEN RECEPTOR;

BREAST CANCER; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EDITORIAL; FEMALE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; META ANALYSIS; MORBIDITY; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SUN EXPOSURE; SYSTEMATIC REVIEW; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; DRUG ANTAGONISM; DRUG POTENTIATION; METHODOLOGY; PATHOLOGIC FRACTURE;

FEMALE; FRACTURES, SPONTANEOUS; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RECEPTORS, ESTROGEN;

EID: 17244383418     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7496.859     Document Type: Editorial

References (12)

1. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359:2018-26.
2. Body JJ, Boonen S, Boutsen Y, De Vogelaer JP, Goemaere S, Kaufman JM, et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: an updated consensus of the Belgian Bone Club. Osteoporos Int 2005 (in press).
3. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Rev 2002;23:570-8.
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
5. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Hip intervention program study group: effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
6. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
7. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
8. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmeaopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
10. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaicli GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone-mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
11. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector T, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
12. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 2005 (in press).